Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Trump Administration Extends Transgender Health Care Ban to Adults, Affecting Thousands
The Trump administration has widened its crackdown on gender‑affirming care, extending bans that once targeted minors to adults. New directives halt transition services at federally funded hospitals, end VA hormone therapy for non‑existing patients and strip federal employee health plans of coverage, leaving thousands of transgender adults without care.
AstraZeneca Secures Positive EU CHMP Opinion for Camizestrant Combo in Advanced Breast Cancer
AstraZeneca announced that the European Medicines Agency’s CHMP has issued a positive opinion on camizestrant combined with a CDK4/6 inhibitor for ER‑positive, HER2‑negative advanced breast cancer with ESR1 mutations. The Phase III SERENA‑6 trial showed a 56% reduction in disease progression...
Do You Think the CNPV Program Has Delivered on It's Promises?
Harpreet Singh, MD, chief medical officer at Precision for Medicine, evaluates the FDA's Commissioner’s National Priority Voucher (CNPV) program, noting it speeds regulatory review after pivotal trials are completed. She highlights voucher use across oncology, antibiotics, pain management and psychedelics,...
Scientists Create Wearable Ultrasound to Continuously Monitor Babies in Womb
Scientists at Stanford and Oxford have unveiled UPatch, a wearable ultrasound patch that can continuously image a fetus for hours, capturing real‑time blood‑flow and heart‑rate data. In a proof‑of‑concept study involving 62 pregnant participants, the device’s measurements closely matched those...
Will Lab-Grown Sperm Let Infertile Men Have Children of Their Own?
A US start‑up, Paterna Biosciences, says it can turn testicular stem cells into sperm in the lab, potentially offering a solution for men whose infertility cannot be treated with existing methods. The company claims the technique could enable almost all...
Cheaper, Alternative Health Plans Are Having a Moment, but Critics Urge Caution
Rising ACA marketplace premiums have driven many consumers toward lower‑cost alternatives such as short‑term, fixed‑indemnity and health‑sharing plans that do not meet federal coverage standards. These plans offer minimal premiums—often under $350 a month—but provide limited benefits, caps on payments,...
STAT+: An AI Biotech CEO Sets the Record Straight on AI Drug Development Hype
BigHat Biosciences CEO Peyton Greenside says her firm can generate antibody designs in as little as 20 minutes using machine‑learning, far faster than the six‑hour demos often touted in the industry. However, she emphasizes that rapid design is only the...
Oticon Medical Launches Ponto Instant Portfolio to Expand Non-Surgical Bone Conduction Hearing Options
Oticon Medical unveiled the Ponto Instant portfolio, a non‑surgical bone‑conduction hearing solution that adds two new wearables: the Instant HearBand and the Instant SoundConnector. The HearBand offers a lightweight, behind‑the‑head design with adjustable sizing, while the SoundConnector lets users attach...
AMA: Healthcare 2026: What Is Driving 3D Printing in Dentistry Toward a $10BN Market Value?
Dentistry’s 3D printing market, valued at roughly $5.2 billion in 2024, is projected to approach $10 billion by 2033. Printer penetration in U.S. practices has risen to about 15%, up from virtually none a decade ago, while entry‑level system costs have collapsed...
Vaccine Litigation and the Future of Public Health Policy
A recent JAMA Forum article examines how vaccine litigation threatens public‑health goals by eroding herd immunity and confusing providers. It outlines the legal tug‑of‑war between religious exemption claims and mandatory vaccination policies. The piece cites recent court rulings that both...
Pierre Fabre’s Braftovi Gains CHMP Positive Opinion for mCRC
The European Medicines Agency’s CHMP issued a positive opinion for Pierre Fabre’s Braftovi (encorafenib) combined with cetuximab and Folfox as a first‑line treatment of BRAFV600E‑mutant metastatic colorectal cancer. The Phase III BREAKWATER trial showed a 51 % reduction in death risk, extending median...
Home Cancer Tests Could Arrive Within a Decade
All such study results indicate that having lab devices at home that work like those machines we have today, only at professional clinical laboratories, is possible in a decade, even for detecting cancer. Just look at this Chinese example: "𝐴 𝑠𝑖𝑛𝑔𝑙𝑒 𝑑𝑟𝑜𝑝...
The European CDMO Model, Powering Biologics Innovation
European contract development and manufacturing organisations (CDMOs) are becoming pivotal as biologics grow in complexity, and 3PBIOVIAN exemplifies this shift with a pan‑European, end‑to‑end model. The company operates GMP‑certified facilities in Pamplona, Spain, and Turku, Finland, offering microbial, mammalian, viral...
AstraZeneca Receives the CHMP Positive Opinion for Camizestrant to Treat Advanced Breast Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on AstraZeneca’s oral selective estrogen receptor degrader camizestrant, to be used with a CDK4/6 inhibitor for ER‑positive, HER2‑negative advanced breast cancer harboring ESR1 mutations....
Imaging Societies Clash over Bill to Require that Docs Consult Appropriate-Use Criteria
The American College of Radiology (ACR) is championing the Radiology Outpatient Ordering Transmission (ROOT) Act, legislation that would revive the CMS appropriate‑use criteria (AUC) program for advanced imaging. ACR CEO Dana H. Smetherman testified that the bill could save the...
Lantheus Weighs Potential Sale with $7B Valuation
Lantheus Holdings, a leading radiopharmaceutical developer, is reportedly entertaining a sale that could fetch a valuation close to $7 billion. Bloomberg cited sources saying Curium Pharma, a nuclear‑medicine specialist owned by CapVest Partners, is the primary suitor. Both companies have declined...
ONWARD Medical Reports First Quarter 2026 Results with Strong Commercial Momentum and Key Clinical Milestones
ONWARD Medical reported Q1 2026 results, delivering 70 ARC‑EX systems and expanding availability to over 100 clinics across the US and Europe. The company launched the Empower BP pivotal study, enrolling its first participant and activating 12 sites to evaluate the ARC‑IM...
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
Isomorphic Labs closed a $2.1 billion Series B to scale its AI drug‑design engine, while CellCentric secured $220 million to push its oral myeloma candidate, inobrodib, into Phase 3 trials. NVision raised $55 million Series B to merge quantum computing with its POLARIS MRI platform, aiming...
Novartis Breaks Ground On Denton, Texas Radioligand Therapy Site
Novartis broke ground on a 46,000‑sq‑ft radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking its first Texas‑based plant and the fifth RLT site in the United States. The project is part of a broader $23 billion five‑year investment to expand...
REGENXBIO, Novartis, Dyne Near FDA Submissions in Muscular Dystrophies
A wave of near‑term regulatory activity is reshaping the muscular dystrophy landscape. REGENXBIO reported mixed Phase 3 data for its gene therapy RGX‑202, achieving 93% microdystrophin expression but raising safety flags, while targeting a 2027 launch. Novartis’ $12 billion acquisition of Avidity...
Is Surrogacy Modern-Day Slavery? What to Know About Florida Republican Effort to Pass Severe Restrictions.
Attorney General James Uthmeier is arguing before Florida's Fourth District Court of Appeal that surrogacy violates the state constitution, calling the practice modern‑day slavery. Governor Ron DeSantis has backed legislation that bans surrogacy contracts with citizens or residents of designated...
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Australian biotech Noxopharm announced new data on its Sofra platform, a TLR8‑activating oligonucleotide technology that could enhance cancer immunotherapy. Preclinical studies demonstrated up to a 200‑fold boost in TLR8 activity in human skin biopsies and nearly three‑fold activation in animal...
Gilead's Trodelvy Wins CHMP Positive Opinion for First‑Line Metastatic Triple‑Negative Breast Cancer
The European Medicines Agency’s CHMP has issued a positive opinion on Gilead’s Trodelvy for first‑line treatment of metastatic triple‑negative breast cancer (mTNBC) in patients who cannot receive PD‑(L)1 inhibitors. The recommendation follows the ASCENT‑03 trial, which showed a 38% reduction...
FDA Grants Priority Review to Bayer's Finerenone for Type 1 Diabetes Kidney Disease
The U.S. FDA accepted Bayer's supplemental NDA and granted priority review to finerenone (Kerendia) for chronic kidney disease in adults with type 1 diabetes. The decision follows a phase‑3 trial that cut urine albumin‑to‑creatinine ratio by about 25% in 242 patients,...
Seoul National University Hospital and Harvard Launch AI-Powered Hospital Simulator
Seoul National University Hospital and Harvard Medical School have introduced the Clinical Environment Simulator, a virtual hospital that evaluates medical AI under realistic, dynamic conditions. The platform uses a dual-engine system to model patient trajectories and hospital workflows, offering a...
JotPsych Launches JotMeet Integrated Telehealth Platform for Mental‑Health Care
JotPsych announced the launch of JotMeet, an integrated telehealth platform designed to simplify virtual mental‑health care delivery. The product bundles video visits, digital intake, and electronic health‑record integration, aiming to expand access and improve clinician workflow. Details on pricing and...
NeuroScientific Hails 80% Clinical Response in Crohn’s Stem Cell Program
NeuroScientific Biopharmaceuticals reported that four of five patients with fistulising Crohn’s disease showed a clinical response to its StemSmart mesenchymal stem cell therapy, an 80% response rate. All participants experienced symptom improvement and no serious adverse events were recorded. The...
Man's Death Confirmed as Diphtheria-Related After Overseas Toxicology Test
The Northern Territory has reported a decline in diphtheria cases after a rapid vaccination campaign that immunised over 10,000 residents. Health officials confirmed one death in Darwin was diphtheria‑related, while another suspected fatality tested negative. Cases fell from a peak...
Old Drugs, New Tricks: FDA’s Drug Repurposing Initiative
On May 11, 2026 the FDA launched a public docket (FDA-2026-N-4492) to gather stakeholder input on its new drug‑repurposing initiative, inviting comments by June 11, 2026. The agency seeks guidance on priority chronic disease areas and on which already‑approved drugs have the strongest potential...
One Hope, One Team: We Hope Medical Group Unites for Compassionate Care
We Hope Medical Group convened its nationwide network of physicians, specialists, and health leaders for the "One Hope, One Team" assembly in Manila, reinforcing its mission to deliver dignified, patient‑centered care across the Philippines. Chairman and CEO Dr. John Paul...
Caliway Secures FDA IND Clearance, Launches Global Phase 3 Trial for CBL‑514
Caliway Biopharmaceuticals received U.S. FDA clearance of its IND for CBL‑514, enabling a global Phase 3 study that will enroll about 320 participants across the United States, Canada and Australia. The trial’s rigorous MRI‑based endpoints aim to set a new efficacy...
EBRI Survey Shows 75% of Insured Workers Face Deductibles, Eroding Financial Protection
The Employee Benefit Research Institute and Greenwald Research released a survey indicating that over 75% of insured employees now carry deductibles, up from 65% a year ago. With employer-sponsored plans still covering about 60% of the workforce, the rise in...
India’s Ayushman Bharat Crosses 100 Crore Digital Health Records
India’s Union Health Ministry and the National Health Authority announced that the Ayushman Bharat Health Account (ABHA) has linked over 100 crore (1 billion) digital health records, doubling the count in just 15 months. The surge, driven by integration of 450 tech...
The Next Frontier For GLP-1 Medications: Potential Therapy For Inflammation
A recent Cell Metabolism study found that semaglutide, a GLP‑1 medication, can alleviate osteoarthritis‑related inflammation and tissue damage independent of its weight‑loss effects. The research showed reduced cartilage degradation, fewer osteophytes, and lower pain sensitivity in pre‑clinical models. With roughly...
2026 HIPAA Security Rule Finalized, Raising the Bar for Employee Health Data Management
The U.S. Office for Civil Rights finalized the 2026 HIPAA Security Rule in May 2026, adding mandatory annual security risk assessments, universal encryption of ePHI and multi‑factor authentication. The new requirements reshape how employers protect employee health information and pressure...
Eli Lilly's VERVE-102 Gene Therapy Cuts PCSK9 and LDL‑C in Phase 1b Heart‑2 Trial
Eli Lilly announced that a single infusion of its investigational base‑editing therapy VERVE-102 produced dose‑dependent reductions in circulating PCSK9 protein and LDL‑C in the Phase 1b Heart‑2 trial of adults with heterozygous familial hypercholesterolemia or premature coronary disease. The FDA...
Asan Medical Center Unveils AI-Powered Private Search System
Asan Medical Center (AMC) in South Korea has launched an AI‑driven knowledge search system that operates entirely within a closed, on‑premises network. The platform combines a vector database with retrieval‑augmented generation (RAG) to deliver context‑aware answers from internal clinical guidelines...
Singapore, Bhutan Partner on Rural Chest X-Ray AI
Singapore’s public health system, SingHealth, has signed a two‑year memorandum of understanding with Bhutan’s Royal University and its Gyalpozhing College of Information Technology to create an AI‑assisted chest X‑ray model. The partnership will adapt the MerMED‑FM foundation model using Bhutanese...
![GLP-1s, Weight Loss, and the Inflammation Tests Your Patient Needs [PODCAST]](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://kevinmd.com/wp-content/uploads/fleming_glp1_thumbnail.png)
GLP-1s, Weight Loss, and the Inflammation Tests Your Patient Needs [PODCAST]
In a KevinMD podcast, cardiologist Richard Fleming argues that GLP‑1 agonists should be evaluated beyond weight loss, emphasizing inflammatory and thrombotic markers as true disease indicators. He critiques reliance on surrogate metrics such as BMI, hemoglobin A1C, and LDL, noting they...
Experts Call for Women's Heart Centers to Tackle Inequality in Diagnosis and Care
A new clinical consensus statement from the European Society of Cardiology calls for dedicated women’s heart centers across Europe to close the gender gap in cardiovascular diagnosis and treatment. The report, led by Dr. Julia Grapsa, highlights that heart disease kills...
Maternal RSV Vaccine Prevents Infant Hospitalizations in Dallas
In Dallas, infant RSV hospitalizations split sharply by maternal vaccination status during the 2023–2024 season. None of the babies whose mothers were vaccinated were hospitalized, but access remained uneven. rsv
New Maternal RSV Vaccine Lowers Infant Hospitalization Rates, but Accessibility May Be Limited, Study Finds
A new maternal RSV vaccine introduced in fall 2023 reduces infant hospitalizations, with the Dallas study showing zero hospitalizations among vaccinated infants versus 3% among unvaccinated. Vaccination rates varied sharply by insurance type and race, with private‑insured mothers at 37%...
Repetitive TMS Effective, Safe for Poststroke Neurogenic Overactive Bladder
A randomized controlled trial of 60 stroke survivors showed that low‑frequency contralesional repetitive transcranial magnetic stimulation (rTMS) significantly improves neurogenic overactive bladder symptoms, quality of life, and resilience scores compared with sham treatment. Benefits persisted through week 8, with mean OAB...
IBio’s Global Clinical Trial Strategy for Advancing Next-Gen Obesity Drugs
iBio is advancing next‑generation obesity therapeutics that go beyond GLP‑1 weight‑loss drugs, focusing on muscle preservation, durability, tolerability, and cardiometabolic complications. The company secured Australian regulatory clearance for a Phase I trial of IBIO‑600, a long‑acting anti‑myostatin antibody designed for infrequent...
Peptides / Bioregulators
Therapeutic peptide development has accelerated over the past decade thanks to new synthesis, modification, and analytical platforms, positioning peptides as a fast‑growing drug class. While FDA‑approved peptides remain limited to GLP‑1 analogues and a handful of niche indications, a flood...
Know Your CAC Score: Key to Heart Attack Prevention
Nobody wants a heart attack or stroke, so prevention is key. Concierge longevity expert Dr. Gregory Charlop explains what the coronary artery calcium score (CAC) is, and who should be tested. www.buckheadlongevity.com/blog/what-are-coronary-artery-calcium-scores-and-who-should-be-tested
Gene Therapy Matures: New Approvals Across Multiple Diseases
The recent approval of new genetic medicines highlights the growing maturation of gene therapy across neurological, retinal, cardiac, hearing, and neuromuscular diseases, with increasingly targeted and potentially safer approaches advancing toward clinical adoption. https://t.co/s25KgpsKqN
Response to Comments on "Aluminium Adjuvants in Vaccines and Potential Health Effects: Systematic Review"
The authors of a BMJ systematic review on aluminium adjuvants in vaccines rebut criticisms by highlighting methodological flaws in cited studies and reaffirming that no causal association has been identified. They note that the Joura 2015 HPV vaccine trial cannot...
Long Incubation, but Detection Keeps Risk Unchanged
The curse of the long incubation period… However —> “Health authorities emphasize that the detection of the case has occurred within the already activated isolation and control system, so it does not alter the risk situation for the general population nor change...
AI‑Guided Ileostomy Selection Cuts Complications in Rectal Cancer Surgery
Researchers reported that a machine‑learning model used to decide when to create temporary diverting ileostomies in rectal cancer surgery lowered ileostomy‑related complications while keeping anastomotic leak rates steady, offering a clear clinical benefit and cost savings.